Mifepristone in Children With Refractory Cushing's Disease
- First Posted Date
- 2013-08-19
- Last Posted Date
- 2014-08-04
- Lead Sponsor
- Corcept Therapeutics
- Registration Number
- NCT01925092
- Locations
- 🇺🇸
National Institute of Child Health and Human Development (NICHD), Bethesda, Maryland, United States
Compassionate Use of CORLUX® (Mifepristone) in the Treatment of Signs and Symptoms of Endogenous Cushing's Syndrome
- First Posted Date
- 2011-06-13
- Last Posted Date
- 2014-03-18
- Lead Sponsor
- Corcept Therapeutics
- Target Recruit Count
- 4
- Registration Number
- NCT01371565
- Locations
- 🇺🇸
The Center for Diabetes and Endocrine Care, Hollywood, Florida, United States
🇺🇸Sinai Hospital of Baltimore, Baltimore, Maryland, United States
🇺🇸University of Michigan Medical Center, Ann Arbor, Michigan, United States
An Extension Study of CORLUX in the Treatment of Endogenous Cushing's Syndrome
- First Posted Date
- 2009-07-10
- Last Posted Date
- 2014-04-02
- Lead Sponsor
- Corcept Therapeutics
- Target Recruit Count
- 30
- Registration Number
- NCT00936741
- Locations
- 🇺🇸
Cleveland Clinic Foundation; Dept of Endocrinology, Diabetes & Metabolism, Cleveland, Ohio, United States
🇺🇸The Center for Diabetes and Endocrine Care, Hollywood, Florida, United States
🇺🇸AMCR Institute Inc., Escondido, California, United States
A Study to Confirm Recurrent or Persistent Cushing's Syndrome in Patients With Signs or Symptoms of Hypercortisolemia
- First Posted Date
- 2008-11-24
- Last Posted Date
- 2014-06-20
- Lead Sponsor
- Corcept Therapeutics
- Target Recruit Count
- 2
- Registration Number
- NCT00796783
- Locations
- 🇺🇸
AMCR Institute Inc., Escondido, California, United States
🇺🇸The Center for Diabetes and Endocrine Care, Hollywood, Florida, United States
🇺🇸Diabetes and Glandular Disease Research, San Antonio, Texas, United States
A Phase I Study to Determine the Effect of Mifepristone on the Pharmacokinetics of Fluvastatin in Healthy Volunteers
- First Posted Date
- 2008-09-16
- Last Posted Date
- 2012-02-17
- Lead Sponsor
- Corcept Therapeutics
- Target Recruit Count
- 20
- Registration Number
- NCT00752843
- Locations
- 🇺🇸
MDS Pharma, Tempe, Arizona, United States
A 4-week Study of Mifepristone in the Prevention of Risperidone-induced Weight Gain in Healthy Male Volunteers
- Conditions
- Interventions
- First Posted Date
- 2008-06-16
- Last Posted Date
- 2022-02-08
- Lead Sponsor
- Corcept Therapeutics
- Target Recruit Count
- 76
- Registration Number
- NCT00698022
- Locations
- 🇮🇳
Dhirubhai Ambani Life Sciences Centre, Mumbai, India
A Study of Mifepristone vs. Placebo in the Treatment of Patients With Major Depression With Psychotic Features
- Conditions
- Interventions
- First Posted Date
- 2008-03-18
- Last Posted Date
- 2017-06-05
- Lead Sponsor
- Corcept Therapeutics
- Target Recruit Count
- 292
- Registration Number
- NCT00637494
- Locations
- 🇺🇸
Inquest Clinical Group/ Global Research Associates, Hope Mills, North Carolina, United States
🇺🇸Collaborative Neuroscience Network, Inc., Garden Grove, California, United States
🇺🇸Breakthrough Clinical Trials, San Bernardino, California, United States
A Study of the Efficacy and Safety of CORLUX in the Treatment of Endogenous Cushing's Syndrome
- First Posted Date
- 2007-12-07
- Last Posted Date
- 2013-08-22
- Lead Sponsor
- Corcept Therapeutics
- Target Recruit Count
- 50
- Registration Number
- NCT00569582
- Locations
- 🇺🇸
Sinai Hospital of Baltimore, Baltimore, Maryland, United States
🇺🇸University of Mississippi Medical Center, Jackson, Mississippi, United States
🇺🇸The Center for Diabetes and Endocrine Care, Hollywood, Florida, United States
A Two-Week Study of the Efficacy and Safety of Mifepristone in the Prevention of Olanzapine-Induced Weight Gain
- Conditions
- First Posted Date
- 2007-04-03
- Last Posted Date
- 2008-09-19
- Lead Sponsor
- Corcept Therapeutics
- Target Recruit Count
- 57
- Registration Number
- NCT00455442
- Locations
- 🇮🇳
St. John's Medical College, Bangalore, India
A United States Extension Study of Corlux for Recurrent Psychotic Symptoms in Psychotic Major Depression
- First Posted Date
- 2005-09-21
- Last Posted Date
- 2012-02-15
- Lead Sponsor
- Corcept Therapeutics
- Target Recruit Count
- 87
- Registration Number
- NCT00208156
- Locations
- 🇺🇸
Claghorn-Lesem Research Clinic, Bellaire, Texas, United States
🇺🇸New Jersey Medical School - UMDNJ, Newark, New Jersey, United States
🇺🇸Cnri, Llc, San Diego, California, United States